• Failed confirmatory trial raises questions about atezolizumab for advanced urothelial cancer

    11 monthes ago - By Healio

    The future of atezolizumab as second-line treatment for urothelial cancer is in question after results of a confirmatory trial indicated the agent failed to extend survival.A phase 2 study showed atezolizumab - a monoclonal antibody designed to bind with PD-L1 - improved tumor response rate and duration of response compared with chemotherapy among patients with locally advanced or metastatic urothelial carcinoma who progressed after prior chemotherapy.
    Read more ...

     

  • VIDEO: Results of LATITUDE trial reinforce long-hypothesized theory in prostate cancer treatment

    11 monthes ago - By Healio

    CHICAGO - The results of the LATITUDE trial demonstrated that the addition of abiraterone acetate with prednisone to standard hormonal therapy led to a decreased risk for death in men with high-risk, metastatic prostate cancer.In this video from the ASCO Annual Meeting, Donald L. “Skip” Trump, MD, FACP, executive director of Inova Schar Cancer Institute and a HemOnc Today Editorial Board member, discusses the results of the trial and its significance.
    Read more ...